Home
About
Overview
Sharing Data
ORCID
Help
History (12)
C. elegans and mutants with chronic nicotine exposure as a novel model of cancer phenotype.
Phase II Study of the AKT Inhibitor MK-2206 plus Erlotinib in Patients with Advanced Non-Small Cell Lung Cancer Who Previously Progressed on Erlotinib.
Durvalumab, with or without tremelimumab, plus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer: 3-year overall survival update from CASPIAN.
Comutations and KRASG12C Inhibitor Efficacy in Advanced NSCLC.
KRAS in Non-Small-Cell Lung Cancer-Reply.
See All 12 Pages
Find People
Find Everything
Login
to edit your profile (add a photo, awards, links to other websites, etc.)
Edit My Profile
My Person List (
0
)
Return to Top
KRAS in Non-Small-Cell Lung Cancer-Reply.
KRAS in Non-Small-Cell Lung Cancer-Reply. JAMA Oncol. 2016 10 01; 2(10):1373-1374.
View in:
PubMed
subject areas
Carcinoma, Non-Small-Cell Lung
Humans
Lung Neoplasms
authors with profiles
Thomas Hensing
Ravi Salgia